Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy - Takeaways - MDSpire

Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy

  • By

  • Danai Dima

  • Al-Ola Abdallah

  • James A. Davis

  • Hussein Awada

  • Utkarsh Goel

  • Aliya Rashid

  • Shaun DeJarnette

  • Faiz Anwer

  • Leyla Shune

  • Shahzad Raza

  • Zahra Mahmoudjafari

  • Louis Williams

  • Beth Faiman

  • Joseph P. McGuirk

  • Craig S. Sauter

  • Nausheen Ahmed

  • Jack Khouri

  • Hamza Hashmi

  • May 31, 2024

  • 0 min

Share

  • 1

    Extramedullary disease (EMD) occurs in 3-14% of relapsed-refractory multiple myeloma patients and is linked to poor prognosis.

  • 2

    Chimeric antigen receptor T-cell therapy has shown promising outcomes in treating relapsed-refractory multiple myeloma.

  • 3

    The presence of EMD before CAR T-cell therapy predicts early disease progression after treatment.

  • 4

    This study analyzed outcomes of 152 RRMM patients treated with CAR T-cell therapy, focusing on those with active EMD.

  • 5

    Statistical analyses were performed to assess the relationship between patient characteristics and CAR T outcomes.

Original Source(s)

Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy

  • by Danai Dima, Al-Ola Abdallah, James A. Davis, Hussein Awada, Utkarsh Goel, Aliya Rashid, Shaun DeJarnette, Faiz Anwer, Leyla Shune, Shahzad Raza, Zahra Mahmoudjafari, Louis Williams, Beth Faiman, Joseph P. McGuirk, Craig S. Sauter, Nausheen Ahmed, Jack Khouri, Hamza Hashmi

  • May 31, 2024

Related Content

Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series

Editorial: A new perspective on the importance of dendritic cells in cancer immunity: from bench to patient’s bedside

Targeting CD38 Enzymatic Function in Antibody-Driven Immunotherapy for Multiple Myeloma: Insights from Basic Research